Multiparametric cell-based assay for the evaluation of transcription inhibition by high-content imaging

Journal of Biomolecular Screening

Volumn 18, Issue 5, 2013, Pages 556-566

  Torres Guzmán, Raquel ^a   Chu, Shaoyou ^b   Velasco, Juan A ^a   Lallena, María José ^a  

^a ELI LILLY AND COMPANY   (Spain)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

assay development; cell cycle; gene transcription; high content imaging; RNA pol II

Indexed keywords

RNA POLYMERASE II;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL ASSAY; CELL CYCLE; CELL CYCLE REGULATION; CELL DIVISION; CELL PROLIFERATION; CELLULAR PARAMETERS; DNA CONTENT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; IC 50; PHENOTYPE; PRIORITY JOURNAL;

ASSAY DEVELOPMENT; CELL CYCLE; GENE TRANSCRIPTION; HIGH-CONTENT IMAGING; RNA POL II;

AUTOMATION, LABORATORY; CALIBRATION; CYCLIN-DEPENDENT KINASES; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HELA CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MICROSCOPY, FLUORESCENCE; PHOSPHORYLATION; RNA POLYMERASE II; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; VALIDATION STUDIES AS TOPIC;

EID: 84878190144     PISSN: 10870571     EISSN: 1552454X     Source Type: Journal    
DOI: 10.1177/1087057112472539     Document Type: Article

References (34)

1. Morgan D. O.. Cyclin-Dependent Kinases: Engines, Clocks and Microprocessors. Annu. Rev. Cell Dev. Biol. 1997 ; 13: 261-291 (Pubitemid 28034527)
2. De Cárcer G., Pérez de Castro I., Malumbres M.. Targeting Cell Cycle Kinases for Cancer Therapy. Curr. Med. Chem. 2007 ; 14: 969-985 (Pubitemid 46672634)
3. Perez de Castro I., De Carcer C., Montoya G., Malumbres M.. Emerging Cancer Therapeutic Opportunities by Inhibiting Mitotic Kinases. Curr. Opin. Pharmacol. 2008 ; 8: 375-383
4. Loyer P., Trembley J. H., Katona R., Kidd V. J., Lahti J. M.. Role of CDK/Cyclin Complexes in Transcription and RNA Splicing. Cell Signal. 2005 ; 17: 1033-1051 (Pubitemid 40933525)
5. Gopinathan L., Ratnacaram C. K., Kaldis P.. Established and Novel Cdk/Cyclin Complexes Regulating the Cell Cycle and Development. Results Probl. Cell Differ. 2011 ; 53: 365-389
6. Glover-Cutter K., Larochelle S., Erickson B., Zhang C., Shokat K., Fisher R. P., Bentley D. L.. TFIIH-Associated Cdk7 Kinase Functions in Phosphorylation of C-terminal Domain Ser7 Residues, Promoter-Proximal Pausing, and Termination by RNA Polymerase II. Mol. Cell. Biol. 2009 ; 29: 5455-5464
7. Judit G., Xavier G.. Cellular Control of Gene Expression by T-type Cyclin/CDK9 Complexes. Gene. 2004 ; 337: 15-23
8. Wang S., Fischer P. M.. Cyclin-Dependent Kinase 9: A Key Transcriptional Regulator and Potential Drug Target in Oncology, Virology and Cardiology. Trends Pharmacol. Sci. 2008 ; 29: 302-313
9. Firestein R., Hahn W. C.. Revving the Throttle on an Oncogene: CDK8 Takes the Driver Seat. Cancer Res. 2009 ; 69: 7899-7901
10. Loo L. H., Wu L. F., Altschuler S. J.. Image-Based Multivariate Profiling of Drug Responses from Single Cells. Nat. Methods. 2007 ; 4: 445-453 (Pubitemid 46901279)
11. Low J., Chakravartty A., Blosser W., Dowless M., Chalfant C., Bragger P., Stancato L.. Phenotypic Fingerprinting of Small Molecule Cell Cycle Kinase Inhibitors for Drug Discovery. Curr. Chem. Genomics. 2009 ; 3: 13-21
12. Low J., Huang S., Blosser W., Dowless M., Burch J., Neubauer B., Stancato L.. High-Content Imaging Characterization of Cell Cycle Therapeutics through In Vitro and In Vivo Subpopulation Analysis. Mol. Cancer Ther. 2008 ; 7: 2455-2463
13. Sittampalam G. S., Iversen P. W., Boadt J. A., Kahl S. D., Bright S., Zock J. M., Janzen W. P., Lister M. D.. Design of Signal Windows in High Throughput Screening Assays for Drug Discovery. J. Biomol. Screen. 1997 ; 2: 159-169 (Pubitemid 127690005)
14. Iversen P. W., Eastwood B. J., Sittampalam G. S., Cox K.. A Comparison of Assay Performance Measures in Screening Assays: Signal Window, Z′ Factor and Assay Variability Ratio. J. Biomol. Screen. 2006 ; 11: 247-252
15. Chen R., Chubb S., Cheng T., Hawtin R. E., Gandhi V., Plunkett W.. Responses in Mantle Cell Lymphoma Cells to SNS-032 Depend on the Biological Context of Each Cell Line. Cancer Res. 2010 ; 70: 6587-6597
16. Zhu Y., Pe'ery T., Peng J., Ramanathan Y., Marshall N., Marshall T., Amendt B., Mathews M. B., Price D. H.. Transcription Elongation Factor p-TEFB Is Required for HIV-Tat Transactivation In Vitro. Genes Dev. 1997 ; 1: 2622-2632 (Pubitemid 27452386)
17. Mancebo H. S., Lee G., Flygare J., Tomassini J., Luu P., Zhu Y., Peng J., Blau C., Hazuda D., Price D., Flores O.. P-TEFb Kinase Is Required for HIV Tat Transcriptional Activation In Vivo and In Vitro. Genes Dev. 1997 ; 11: 2633-2644 (Pubitemid 27452387)
18. Bushnell D. A.. Structural Basis of Transcription: Alpha-Amanitin-RNA Polymerase II Cocrystal at 2.8 A Resolution. Proc. Natl. Acad. Sci. U. S. A. 2002 ; 99: 1218-1222 (Pubitemid 34136473)
19. Trask D. K., Muller M. T.. Stabilization of Type I Topo-isomerase DNA Covalent Complexes by Actimonycin D. Proc. Natl. Acad. Sci. U. S. A. 1988 ; 85: 1417-1421
20. Sedlacek H. H.. Mechanisms of Action of Flavopiridol. Crit. Rev. Oncol. Hematol. 2001 ; 38: 139-170 (Pubitemid 32328317)
21. Rong C., Michael J., Keating V. G., Plunkett W.. Transcription Inhibition by Flavopiridol: Mechanism of Chronic Lymphocytic Leukemia Cell Death. Blood. 2005 ; 106: 2513-2519 (Pubitemid 41510827)
22. Chao S. H., Price D. H.. Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription In Vivo. J. Biol. Chem. 2001 ; 276: 31793-31799
23. Harrington E. A., Bebbington D., Moore J., Rasmussen R. K., Ajose-Adeogun A. O., Nakayama T., Graham J. A., Demur C., Hercend T., Diu-Hercend A., et al. VX-680, a Potent and Selective Small-Molecule Inhibitor of the Aurora Kinases, Suppresses Tumor Growth In Vivo. Nat. Med. 2004 ; 10: 262-267 (Pubitemid 38667616)
24. Taylor S., Peters J. M.. Polo and Aurora Kinases: Lessons Derived from Chemical Biology. Curr. Opin. Cell. Biol. 2008 ; 20: 77-84
25. Mortlock A. A., Foote K. M., Heron N. M., Jung F. H., Pasquet G., Lohmann J. J., Warin N., Renaud F., De Savi C., Roberts N. J., et al. Discovery, Synthesis, and In Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase. J. Med. Chem. 2007 ; 50: 2213-2224 (Pubitemid 46683074)
26. Gumireddy K., Reddy M. V., Cosenza S. C., Boominathan R., Baker S. J., Papathi N., Jiang J., Holland J., Reddy E. P.. ON01910, a Non-ATP-Competitive Small Molecule Inhibitor of Plk1, Is a Potent Anticancer Agent. Cancer Cell. 2005 ; 7: 275-286 (Pubitemid 40568686)
27. Conroy A., Stockett D. E., Walker D., Arkin M. R., Hoch U., Fox J. A., Hawtin R. E.. SNS-032 Is a Potent and Selective CDK 2, 7 and 9 Inhibitor That Drives Target Modulation in Patient Samples. Cancer Chemother. Pharmacol. 2009 ; 64: 723-732
28. Chen R., Keating M. J., Gandhi V., Plunkett W.. Transcription Inhibition by Flavopiridol: Mechanism of Chronic Lymphocytic Leukemia Cell Death. Blood. 2005 ; 106: 2513-2519 (Pubitemid 41510827)
29. Seong Y. S., Min C., Li L., Yang J. Y., Kim S. Y., Cao X., Kim K., Yuspa S. H., Chung H. H., Lee K. S.. Characterization of a Novel Cyclin-Dependent Kinase 1 Inhibitor, BMI-1026. Cancer Res. 2003 ; 63: 7384-7391 (Pubitemid 37413480)
30. Toogood P. L., Harvey P. J., Repine J. T., Sheehan D. J., VanderWel S. N., Zhou H., Keller P. R., McNamara D. J., Sherry D., Zhu T., et al. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6. J. Med. Chem. 2005 ; 48: 2388-2406 (Pubitemid 40516432)
31. Joseph E.W., Pratilas C. A., Poulikakos P. I., Tadi M., Wang W., Taylor B. S., Halilovic E., Persaud Y., Xing F., Viale A., et al. The RAF Inhibitor PLX4032 Inhibits ERK Signaling and Tumor Cell Proliferation in a V600E B-RAF-Selective Manner. Proc. Natl. Acad. Sci. U. S. A. 2010 ; 107: 14903-14908
32. Meijer L., Raymond E.. Roscovitine and Other Purines as Kinase Inhibitors: From Starfish Oocytes to Clinical Trials. Acc. Chem. Res. 2003 ; 36: 417-425
33. Vassilev L. T., Tovar C., Chen S., Knezevic D., Zhao X., Sun H., Heimbrook D. C., Chen L.. Selective Small-Molecule Inhibitor Reveals Critical Mitotic Functions of Human CDK1. Proc. Natl. Acad. Sci. U. S. A. 2006 ; 103: 10660-10665 (Pubitemid 44078033)
34. Krystof V., Uldrijan S.. Cyclin-Dependent Kinase Inhibitors as Anticancer Drugs. Curr. Drug Targets. 2010 ; 11: 291-302